September 26, 2020

The Niche

Knoepfler lab stem cell blog

MPM Capital

2 min read

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston Globe, there is a good deal of enthusiasm about the potential of this kind of therapeutic approach: “This would be a huge breakthrough,” said Dr. George L. King, a …Read More